397 related articles for article (PubMed ID: 29685879)
1. Clinicopathological Risk Factors for an Invasive Breast Cancer Recurrence after Ductal Carcinoma
Visser LL; Elshof LE; Schaapveld M; van de Vijver K; Groen EJ; Almekinders MM; Bierman C; van Leeuwen FE; Rutgers EJ; Schmidt MK; Lips EH; Wesseling J
Clin Cancer Res; 2018 Aug; 24(15):3593-3601. PubMed ID: 29685879
[No Abstract] [Full Text] [Related]
2. The effects of contemporary treatment of DCIS on the risk of developing an ipsilateral invasive Breast cancer (iIBC) in the Dutch population.
Alaeikhanehshir S; Schmitz RSJM; van den Belt-Dusebout AW; van Duijnhoven FH; Verschuur E; van Seijen M; Schaapveld M; Lips EH; Wesseling J;
Breast Cancer Res Treat; 2024 Feb; 204(1):61-68. PubMed ID: 37964135
[TBL] [Abstract][Full Text] [Related]
3. Subsequent risk of ipsilateral and contralateral invasive breast cancer after treatment for ductal carcinoma in situ: incidence and the effect of radiotherapy in a population-based cohort of 10,090 women.
Elshof LE; Schaapveld M; Schmidt MK; Rutgers EJ; van Leeuwen FE; Wesseling J
Breast Cancer Res Treat; 2016 Oct; 159(3):553-63. PubMed ID: 27624164
[TBL] [Abstract][Full Text] [Related]
4. Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis.
Kerlikowske K; Molinaro AM; Gauthier ML; Berman HK; Waldman F; Bennington J; Sanchez H; Jimenez C; Stewart K; Chew K; Ljung BM; Tlsty TD
J Natl Cancer Inst; 2010 May; 102(9):627-37. PubMed ID: 20427430
[TBL] [Abstract][Full Text] [Related]
5. The prognostic role of HER2 expression in ductal breast carcinoma in situ (DCIS); a population-based cohort study.
Borgquist S; Zhou W; Jirström K; Amini RM; Sollie T; Sørlie T; Blomqvist C; Butt S; Wärnberg F
BMC Cancer; 2015 Jun; 15():468. PubMed ID: 26062614
[TBL] [Abstract][Full Text] [Related]
6. Long-term risk of subsequent ipsilateral lesions after surgery with or without radiotherapy for ductal carcinoma in situ of the breast.
van Seijen M; Lips EH; Fu L; Giardiello D; van Duijnhoven F; de Munck L; Elshof LE; Thompson A; Sawyer E; Ryser MD; Hwang ES; Schmidt MK; Elkhuizen PHM; ; Wesseling J; Schaapveld M
Br J Cancer; 2021 Nov; 125(10):1443-1449. PubMed ID: 34408284
[TBL] [Abstract][Full Text] [Related]
7. Histological type and marker expression of the primary tumour compared with its local recurrence after breast-conserving therapy for ductal carcinoma in situ.
Bijker N; Peterse JL; Duchateau L; Robanus-Maandag EC; Bosch CA; Duval C; Pilotti S; van de Vijver MJ
Br J Cancer; 2001 Feb; 84(4):539-44. PubMed ID: 11207051
[TBL] [Abstract][Full Text] [Related]
8. Breast adipocyte size associates with ipsilateral invasive breast cancer risk after ductal carcinoma in situ.
Almekinders MMM; Schaapveld M; Thijssen B; Visser LL; Bismeijer T; Sanders J; Isnaldi E; Hofland I; Mertz M; Wessels LFA; Broeks A; Hooijberg E; Zwart W; Lips EH; ; Desmedt C; Wesseling J
NPJ Breast Cancer; 2021 Mar; 7(1):31. PubMed ID: 33753731
[TBL] [Abstract][Full Text] [Related]
9. Including the Ductal Carcinoma-In-Situ (DCIS) Score in the Development of a Multivariable Prediction Model for Recurrence After Excision of DCIS.
Paszat L; Sutradhar R; Zhou L; Nofech-Mozes S; Rakovitch E
Clin Breast Cancer; 2019 Feb; 19(1):35-46. PubMed ID: 30190195
[TBL] [Abstract][Full Text] [Related]
10. Her2 and Ki67 Biomarkers Predict Recurrence of Ductal Carcinoma in Situ.
Davis JE; Nemesure B; Mehmood S; Nayi V; Burke S; Brzostek SR; Singh M
Appl Immunohistochem Mol Morphol; 2016 Jan; 24(1):20-5. PubMed ID: 26317313
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of histopathological DCIS features in a large-scale international interrater reliability study.
Groen EJ; Hudecek J; Mulder L; van Seijen M; Almekinders MM; Alexov S; Kovács A; Ryska A; Varga Z; Andreu Navarro FJ; Bianchi S; Vreuls W; Balslev E; Boot MV; Kulka J; Chmielik E; Barbé E; de Rooij MJ; Vos W; Farkas A; Leeuwis-Fedorovich NE; Regitnig P; Westenend PJ; Kooreman LFS; Quinn C; Floris G; Cserni G; van Diest PJ; Lips EH; Schaapveld M; Wesseling J;
Breast Cancer Res Treat; 2020 Oct; 183(3):759-770. PubMed ID: 32734520
[TBL] [Abstract][Full Text] [Related]
12. Multiple foci of microinvasion is associated with an increased risk of invasive local recurrence in women with ductal carcinoma in situ treated with breast-conserving surgery.
Rakovitch E; Sutradhar R; Lalani N; Nofech-Mozes S; Gu S; Goldberg M; Hanna W; Fong C; Paszat L
Breast Cancer Res Treat; 2019 Nov; 178(1):169-176. PubMed ID: 31325071
[TBL] [Abstract][Full Text] [Related]
13. Comparison of ipsilateral breast tumor recurrence after breast-conserving surgery between ductal carcinoma in situ and invasive breast cancer.
Choi YJ; Shin YD; Song YJ
World J Surg Oncol; 2016 Apr; 14():126. PubMed ID: 27122132
[TBL] [Abstract][Full Text] [Related]
14. Risk of subsequent in situ and invasive breast cancer in human epidermal growth factor receptor 2-positive ductal carcinoma in situ.
Curigliano G; Disalvatore D; Esposito A; Pruneri G; Lazzeroni M; Guerrieri-Gonzaga A; Luini A; Orecchia R; Goldhirsch A; Rotmensz N; Bonanni B; Viale G
Ann Oncol; 2015 Apr; 26(4):682-687. PubMed ID: 25600567
[TBL] [Abstract][Full Text] [Related]
15. Clinical risk score to predict likelihood of recurrence after ductal carcinoma in situ treated with breast-conserving surgery.
Punglia RS; Jiang W; Lipsitz SR; Hughes ME; Schnitt SJ; Hassett MJ; Nekhlyudov L; Achacoso N; Edge S; Javid SH; Niland JC; Theriault RL; Wong YN; Habel LA
Breast Cancer Res Treat; 2018 Feb; 167(3):751-759. PubMed ID: 29079937
[TBL] [Abstract][Full Text] [Related]
16. HER2/neu and Ki-67 expression predict non-invasive recurrence following breast-conserving therapy for ductal carcinoma in situ.
Rakovitch E; Nofech-Mozes S; Hanna W; Narod S; Thiruchelvam D; Saskin R; Spayne J; Taylor C; Paszat L
Br J Cancer; 2012 Mar; 106(6):1160-5. PubMed ID: 22361634
[TBL] [Abstract][Full Text] [Related]
17. Characteristics associated with recurrence among women with ductal carcinoma in situ treated by lumpectomy.
Kerlikowske K; Molinaro A; Cha I; Ljung BM; Ernster VL; Stewart K; Chew K; Moore DH; Waldman F
J Natl Cancer Inst; 2003 Nov; 95(22):1692-702. PubMed ID: 14625260
[TBL] [Abstract][Full Text] [Related]
18. Carcinoma in situ of the female breast. A clinico-pathological, immunohistological, and DNA ploidy study.
Ottesen GL
APMIS Suppl; 2003; (108):1-67. PubMed ID: 12874968
[TBL] [Abstract][Full Text] [Related]
19. A population-based validation study of the DCIS Score predicting recurrence risk in individuals treated by breast-conserving surgery alone.
Rakovitch E; Nofech-Mozes S; Hanna W; Baehner FL; Saskin R; Butler SM; Tuck A; Sengupta S; Elavathil L; Jani PA; Bonin M; Chang MC; Robertson SJ; Slodkowska E; Fong C; Anderson JM; Jamshidian F; Miller DP; Cherbavaz DB; Shak S; Paszat L
Breast Cancer Res Treat; 2015 Jul; 152(2):389-98. PubMed ID: 26119102
[TBL] [Abstract][Full Text] [Related]
20. Characteristics of second breast events among women treated with breast-conserving surgery for DCIS in the community.
Hassett MJ; Jiang W; Habel LA; Nekhlyudov L; Achacoso N; Acton L; Schnitt SJ; Schrag D; Punglia RS
Breast Cancer Res Treat; 2016 Feb; 155(3):541-9. PubMed ID: 26843057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
